Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/1065| Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department | |
| Brown, C Noble, J Coralic, Z | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.2 We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective. | |
| Western Journal of Emergency Medicine | |
| 2020 | |
| Preimpreso | |
| https://coronavirus.1science.com/item/9869a0188ae57f9381e8903c8e58aa8d35c5663d | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 105151.pdf | 425.4 kB | Adobe PDF | Visualizar/Abrir |